Introduction
Advanced melanoma is the beˆte noire of clinical oncology. Although other tumor types account for a larger number of annual cancer deaths, melanoma is noteworthy for its intense therapeutic resistance, aggressive clinical behavior, and proclivity for late metastasis. Medical oncology has made virtually no progress in the treatment of advanced melanoma, and there continues to be no therapeutic regimen shown to improve the survival of patients in randomized trials. Furthermore, in contrast to the declining incidence for many tumor types, the incidence of melanoma has increased steadily for the last three decades, a likely outcome of increased recreational UVB exposure ( Figure 1 ). This dreadful clinical and epidemiological picture demands an improved understanding of disease pathogenesis.
On the genetic level, the signature events in melanoma include activation of the Ras/Raf pathway (Davies et al., 2002; Herlyn and Satyamoorthy, 1996) and loss of INK4a/ARF locus function (Flores et al., 1996; Walker et al., 1998) . Indeed, mice deficient of INK4a/ARF and engineered to express activated H-RAS in melanocytes succumb to highly invasive melanomas early in life (Chin et al., 1997) . In humans, deletion of INK4a/ARF is a common genetic lesion detected in B50% of primary tumors and nearly all melanoma cell lines (Flores et al., 1996; Walker et al., 1998) . This locus encodes two distinct proteins, p16
INK4a and p14 ARF (p19 ARF in the mouse), both of which demonstrate tumor suppressor activity in genetically distinct anticancer pathways (i.e. the 'Rb pathway' for p16
INK4a and the 'p53 pathway' for p14 ARF ) (Ruas and Peters, 1998; Sharpless and DePinho, 1999) . It is not known, however, if these somatic lesions target p16 INK4a , p14 ARF , both, or closely linked gene(s) such as MTAP (Schmid et al., 1998) 
or p15
INK4b (Figure 2 ). Likewise, while melanoma is associated with UV exposure and history of sunburn in humans and mice (Gilchrest et al., 1999; Noonan et al., 2001) , the molecular basis for UV-induced tumorigenesis and, specifically, the role of the Ink4a/Arf locus in UVmediated melanoma development, are not known. This work will review recent data from both human melanoma genetics and murine models that clearly establishes a role for both p16
INK4a and p14 ARF in melanoma suppression. We also speculate as to the functional consequences of loss of these proteins in human melanoma and point to data indicating that p16
INK4a inactivation is a rate-limiting step in UVinduced melanoma in mice. INK4a was identified initially as a CDK4-associated protein capable of inhibiting CDK4/6-mediated phosphorylation of the retinoblastoma tumor suppressor protein (pRb) (Serrano et al., 1993) . Since hypophosphorylated pRb binds to and represses E2F transcriptional activity and constrains G1 exit, p16
INK4a expression results in cell cycle arrest (Figure 3a) . The link of p16
INK4a to human cancer was established following its localization to a key cancer hot spot, the CDKN2a locus at 9p21, which is the target of deletion in many types of human cancers (Kamb et al., 1994a) . Germline point mutations of p16
INK4a were noted to cosegregate with tumor susceptibility in kindreds with familial melanoma (Hussussian et al., 1994; Kamb et al., 1994b; Holland et al., 1995; Liu et al., 1995; Walker et al., 1995) , and somatic loss (through deletion, point mutation, or promoter methylation) of p16
INK4a is among the most common events in human cancer (Table 1) (reviewed in Ruas . The importance of p16
INK4a has been further reinforced by finding of alterations that target its biochemical partners, that is, CDK4 point mutation that inhibits its binding to p16
INK4a (Wolfel et al., 1995; Zuo et al., 1996) or CDK6 overexpression (Tang et al., 1999) . Thus, dysregulation of cyclin-dependent kinase activity is a hallmark of melanoma formation.
In dissecting how p16 INK4a might exert its cancer suppression activities, numerous studies have shown accumulation of p16
INK4a in response to diverse cancerrelevant stimuli including passage in culture, growth at high density, DNA damage, oncogene activation, and advancing age (Alcorta et al., 1996; Reznikoff et al., 1996; Serrano et al., 1997; Robles and Adami, 1998; Shapiro et al., 1998; Zindy et al., 1998; Pavey et al., 1999; Wieser et al., 1999; Piepkorna, 2000) . Mice lacking p16
INK4a are phenotypically normal except prone to tumors and sensitive to carcinogens (see below and Krimpenfort et al., 2001; Sharpless et al., 2001) . These data suggest that p16
INK4a plays little or no role in normal development, but instead serves to limit inappropriate or aberrant cellular proliferation. Data correlating a polymorphism of an INK4 protein and susceptibility to UV-induced melanoma in fish suggest that this role in abrogating neoplasia is conserved over a large phylogenetic distance (Nairn et al., 1996) , and tumor-permissive hypomorphic mutations have also been found in mice (Zhang et al., 1998a) and humans (listed in Ruas and .
The existence of a 'beta transcript' at the INK4a/ARF locus was noted soon after the cloning of p16
INK4a (Duro et al., 1995; Mao et al., 1995; Stone et al., 1995) , although this transcript was initially thought to be noncoding. The beta transcript originates from an exon (exon 1b) 13 kb upstream of the first exon (exon 1a) for p16 INK4a , and is spliced to a common second exon Figure 2 ). Sherr and colleagues, however, appreciated that the beta transcript indeed was translated into a protein which they called 'ARF' (for alternative reading frame) as, remarkably, the two ORFs encode proteins in ARFs of the shared second and third exons (Quelle et al., 1995) . Therefore, p16
INK4a and p19 ARF are not isoforms and share no amino-acid homology.
The initial clues to ARF function came from the observation that its expression induced a cell-cycle arrest that could not be abrogated by D-type cyclin expression (Quelle et al., 1995) . Furthermore, p19 ARF overexpression was noted in p53-null cells and its loss obviated the requirement for p53 inactivation to immortalize murine fibroblasts (Kamijo et al., 1997) . In addition, tumors from mice lacking ARF were noted to contain intact p53 function (Chin et al., 1997) , suggesting that ARF and p53 reside in a common genetic pathway. This view was further refined by the observation that p19 ARF potently inhibited the transformation of murine fibroblasts by MDM2, but p19 ARF had no effect on transformation in cell lacking p53 (Pomerantz et al., 1998) ; suggesting ARF might play a role in the regulation of the MDM2-mediated degradation of p53. These genetic results were strengthened biochemically through a number of approaches by the demonstration that ARF binds MDM2 and inhibits the ubiquitination of p53, thereby stabilizing this archetypal tumor suppressor protein (Figure 3b ) Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998b) . Provocatively, ARF was also found to be a mediator of p53-dependent apoptosis in the lens in response to the cell-cycle dysregulation associated with Rb deficiency (Pomerantz et al., 1998) , suggesting that ARF-linked oncogenic stress to p53. Several forms of oncogenic stress including expression of v-abl (Radfar et al., 1998) , c-myc ), E1a (de Stanchina et al., 1998 , or loss of Rb have since been demonstrated to induce ARF and thereby stabilize p53. Lastly, mice with targeted disruption of exon 1b (affecting p19 ARF but not p16
INK4a
) develop lymphoma, sarcoma, and carcinoma (Kamijo et al., 1997 (Kamijo et al., , 1999 , establishing p19 ARF as a bona fide tumor suppressor gene.
Recent genetic evidence in human cancers clearly supports and complements the p19 ARF tumor suppressor data derived from the mouse. Germline mutations affecting p14 ARF , but not p16
, have been associated with familial melanoma and astrocytoma (RandersonMoor et al., 2001; Rizos et al., 2001) , and somatic loss of p14 ARF is seen in numerous human tumors (Ruas and Peters, 1998) . Also, oncogenic transcription factors such as Twist (Maestro et al., 1999) and AML-ETO (Linggi et al., 2002) , which are thought to play a role in tumor formation, have been shown specifically to repress p14 ARF . Together, these data suggest that ARF, like p16 INK4a may also serve to displace p21/p27 from cyclin D/cdk4 complexes, and thus indirectly regulate cyclin E/cdk2 activity. Through both mechanisms, p16
INK4a serves to increase the abundance of hypophosphorylated Rb, which antagonizes the proliferative stimulus of E2F1-3. While the role of ARF in stabilizing p53 by inhibiting its MDM2-mediated ubiquitinylation, controversy exists as to whether ARF has p53-independent functions. Also, ARF is potently induced in both murine and human cells by certain oncogenic stimuli, but its role in p53 induction in response to DNA damage is less clear Figure 2 The human INK4a/ARF locus. The murine Ink4a/Arf locus in melanoma
The role of p16 INK4a and/or p19 ARF in melanoma was genetically established in a murine system by the demonstration that loss of exons 2 and 3 (disrupting both p19 ARF and p16
) could cooperate with overexpression of an activated H-RAS transgene in melanocytes (Tyrosinase-RAS or Tyr-RAS) to induce melanoma (Chin et al., 1997) . In this model, the animals developed tumors with high penetrance and a median latency of 22 weeks. These tumors were characteristic amelanotic melanomas of the dermis, which were locally invasive but possessed a very low propensity to metastasize (for histological images and annotation, see http://cancerimages.nci.nih.gov). In Tyr-RAS Ink4a/ Arf þ /À mice, melanomas formed with a much longer latency than in the Tyr-RAS Ink4a/ArfÀ/À background, and LOH of the wild-type Ink4a/Arf allele was observed in all tumors. Furthermore, such deletions affected the shared exon 2 in 100% of the cases, thus eliminating both p16
INK4a and p19 ARF . As noted above, none of the tumors from Tyr-RAS Ink4a/ArfÀ/À mice sustained p53 loss, providing the genetic clue that p19 ARF and p53 were in a common pathway. Since Ink4a/Arf is lost early in the development of human melanomas, these data provided a rational explanation for the very low incidence of p53 mutations in this specific tumor type.
These observations were further refined by crossing the Tyr-RAS mice to animals lacking p53 . RAS transgenic animals lacking p53 also were highly prone to melanoma, with a tumor latency and histological presentation comparable to that of Tyr-RAS Ink4a/ArfÀ/À mice. However, on the genetic level, p16
INK4a was overexpressed and a candidate survey of Rb pathway components failed to detect alterations of cdk4, cyclin D1, or Rb. Employing a genome-wide scan and subsequent transcriptional analysis, the c-myc locus was found to be amplified and overexpressed in a large proportion of these tumors. This result can be interpreted as either p53 loss obviates the need for p16 INK4a loss, or more likely that myc overexpression can serve as an 'Rb pathway' lesion in these tumors as has been suggested (Daksis et al., 1994; Galaktionov et al., 1996; Vlach et al., 1996; Alevizopoulos et al., 1997; Berns et al., 1997; Bouchard et al., 1999; Hermeking et al., 2000; O'Hagan et al., 2000; Santoni-Rugiu et al., 2000) . Taken with the Tyr-RAS Ink4a/ArfÀ/À result, these data strongly indicate that the p19 ARF -p53 pathway suppresses RAS-induced melanoma formation.
A different system provided further support for the role of the Rb pathway in melanoma. Sotillo et al. (2001) treated mice with a mutant cdk4 (R24C) allele knocked into the murine cdk4 locus with topical carcinogens and monitored these animals for tumor formation . In this system, the activated cdk4 allele does not bind INK4-class inhibitors and thus cannot be inhibited by p16
INK4a or other members of the INK4 family. These mice develop a large number of melanocytic tumors and invasive melanomas after carcinogen exposure (DMBA þ TPA or DMBA þ UV). Of interest, these tumors did not show Ink4a/Arf loss, nor p53 mutation, although a low incidence of N-Ras mutation was found. In addition, the authors showed modest cooperation between p18 INK4c loss and DMBA þ TPA exposure in the generation of melanoctyic lesions. These data suggest that in this melanoma model, there is specific targeting of the Rb-INK4a-cdk4 pathway, with apparent preservation of thep19 ARF -p53 pathway. To validate further the individual roles of p16
INK4a and p19 ARF in murine melanoma, targeted alleles of only p16
INK4a or only p19 ARF have been generated and characterized. Of interest, animals specifically deficient of p16
INK4a (p16
À/À) demonstrate a low frequency of melanoma spontaneously or after DMBA exposure, which is significantly increased in the setting of p19 ARF haploinsufficiency (Krimpenfort et al., 2001; Sharpless et al., 2001 Sharpless et al., , 2002 . On the other hand, mice with exclusive targeting of p19 ARF do not develop melanoma spontaneously or after DMBA exposure (Kamijo et al., 1999 and NES, unpublished 
observations). Of note, either p16
INK4a or p19 ARF loss facilitates melanoma formation in the Tyr-RAS system, with Tyr-RAS p16
INK4a À/À mice developing tumor melanomas at 75 weeks, and Tyr-RAS þ p19 ARF À/À at 40 weeks (vs 24 weeks for Tyr-RAS þ Ink4a/ArfÀ/Àmice) (Sharpless and Chin, unpublished observation) (Figure 4) . Furthermore, Rb pathway lesions are generally found in melanomas from p19 ARF À/À mice, while p53 pathway lesions can be detected in p16
INK4a À/À tumors. These data settle unequivocally that both tumor suppressors of the Ink4a/Arf locus play prominent roles in melanoma formation.
Molecular targets of UV in melanoma
The epidemiologic correlation between history of sunburn and melanoma is strong (Zanetti et al., 1992;  INK4a and p19 ARF status. N420 mice for each cohort, and all curves differ significantly (po0.01) from Tyr-RAS p16
INK4a þ / þ p19 ARF þ / þ mice when compared pairwise by the log-rank test. Animals with nonmelanoma tumors were censored from the analysis Harrison et al., 1994) and UV can directly induce melanocytic lesions and melanoma in human skin grafts (Atillasoy et al., 1998; Berking et al., 2002) . The mechanism, however, whereby UV light induces melanoma has not been determined. There are several nonmutually exclusive theories of UV-induced carcinogenesis; for example, UV has been suggested to act as a melanocyte mitogen (Gilchrest et al., 1999) , induce the production of tumor-promoting paracrine factors (Jamal and Schneider, 2002) , or attenuate antitumor immune surveillance (Donawho and Kripke, 1991) . The most subscribed theory of UV-induced carcinogenesis is that it acts as a global mutagen, but in this model, the molecular targets of UV-induced mutagenesis are not known. While the observation of the so-called 'UVsignature' C4T point mutations of p16
INK4a in human melanoma suggested its targeting by UV light (Pollock et al., 1996) , the finding of a similar mutation bias in glioma (reviewed in Ruas and has called this conclusion into question.
While either p16 INK4a or p19 ARF loss cooperates with RAS pathway activation to induce melanoma, striking differences were noted in the susceptibilities of these strains to UV-inducing effects in melanoma formation. While there was a significant decrease in the tumor latency in UV-treated Tyr-RAS p19 ARF À/À mice relative to untreated Tyr-RAS p19 ARF À/À controls, no cooperation was seen between UV light and p16
INK4a deficiency (Kannan et al., 2003) . While this lack of tumor facilitation seen in UV-treated Tyr-RAS p16
INK4a À/À animals can be interpreted in alternate ways, we subscribe to the view that UV specifically targets the Rb pathway, and therefore adds little to p16
INK4a loss. In line with this notion, a candidate gene survey of UVinduced Tyr-RAS p19 ARF À/À melanomas revealed a high frequency of cdk6 amplification, which was mutually exclusive with p16
INK4a loss in that cohort. Therefore, it appears that, in the Tyr-RAS system, UV light primarily serves to target the Rb pathway, and therefore cooperates efficiently with p19 ARF , but not p16
INK4a loss. These data do not support the view that p16
INK4a plays a major role in the damage response to UV as suggested (Pavey et al., 1999; Piepkorn, 2000; Pavey et al., 2001) , but rather suggest that it or other Rb-pathway components are targeted by UV. Of note, while cdk6 amplification and p16
INK4a loss were detected in UV-induced Tyr-RAS p19 ARF À/À melanoma, Rb loss was not. Therefore, these data do not exclude the possibility of an Rb-independent function of p16 INK4a and cdk6 in melanoma as has been suggested (Fahraeus and Lane, 1999) . Finally, as these tumors all expressed an activated form of H-Ras, these experiments do not address the existence of UV targets in the RAS/RAF pathway.
Conclusions and challenges
The body of evidence presented has firmly established that both the Rb and p53 pathways are breached in melanoma, and also that p16
INK4a and p14 ARF (rather than Rb and p53 themselves) are the 'weakest links' of these pathways in this tumor type. It is likely that the corequirement for loss of these proteins explains several unusual features of melanoma genetics. For example, both p14 ARF -p53 and p16
INK4a
-Rb inactivation may be required as a result of the near obligate RAS/RAFpathway activation seen in these tumors. If so, the preference for p53-pathway inactivation by p14 ARF loss, as opposed to the dominant-negative p53 point mutation seen commonly in epithelial tumors, however, makes sense, because the former lesion also targets p16
. Similarly, the strong preference in melanoma for p16
INK4a deletion -as opposed to other forms of Rbpathway lesion such as p16
INK4a promoter methylation, cyclin D1 amplification, Rb loss, or CDK4 point mutation (e.g. see Table 1 ) -likely reflects the need to target p14 ARF . These hypotheses lead to an intriguing question however: given that a single deletion can target both the Rb and p53 pathways in melanoma, why isn't INK4a/ARF loss favored in all types of malignancy? There are several possible explanations. First, loss of p14 ARF does not disable the DNA-damage arm of the p53 pathway to the same extent as p53 inactivation (Figure 3b ), but DNA instability may be required for certain tumors, especially carcinomas of adults. If these tumors necessarily require a period of genomic instability, as that seen in the setting of critical telomere shortening for example, then some other p53 pathway lesion would still be required, even in the setting of p14 ARF inactivation. Melanocytes, on the other hand, may harbor an intrinsic resistance to DNA damage (see below), and therefore targeting of p14
ARF with intact p53 function may be sufficient for tumor formation in this cell type. Alternatively, as in the case of certain neuroendocrine tumors, there may be other regulators of the Rb pathway such as p18
INK4d that inhibit tumorigenesis even when p16
INK4a is inactivated. Lastly, it is possible that certain tumor-promoting mutations, for example, cyclin D1 overexpression in breast cancer or Twist overexpression in rhabdomyosarcoma, target other tumorigenic pathways in these tissues beyond Rb and p53, and therefore these mutations are preferentially noted in those tumor types.
If the sole lesion of the p53 pathway were p14 ARF loss, one would expect melanoma to be sensitive to DNAdamaging agents (Figure 3b ). Melanoma is characterized, however, by marked chemo-and radioresistance, suggesting that another genetic lesion in addition to INK4a/ARF loss accounts for the resistance to DNA damage of these cancers. The basis for the attenuation of p53-mediated, DNA-damage-induced apoptosis is not known, but a strong candidate is loss of APAF-1, a mediator of apoptosis frequently inactivated in human melanoma (Soengas et al., 2001 , see also Soengas and Lowe in this issue). Likewise, it has been suggested that p16
INK4a loss itself may contribute to a DNA damagemediated growth arrest (Robles and Adami, 1998; Shapiro et al., 1998; Schmitt et al., 2002) , and therefore its loss may also contribute to chemo-and radioresistance. While this may be the case in malignant cells, our data showing no acceleration of tumorigenesis after UV treatment in Tyr-RAS p16
À/À mice suggests that p16
INK4a does not principally function to maintain genomic integrity in nontransformed melanocytes.
Instead, these data suggest a different mechanism whereby UV light promotes melanoma. The enhancement of tumorigenesis in Tyr-RAS p19 ARF À/À but not in Tyr-RAS p16
INK4a À/À mice suggests that p16 INK4a loss and UV treatment are functionally equivalent in this tumor model, and the high frequency of cdk6 amplification in these tumors supports this view. As UV exposure may precede the overt development of melanoma by decades, this observation suggests a way to risk stratify the large number of individuals thought to be at increased risk for melanoma, because of a history of significant sun exposure. Dysplastic nevi from such patients could be screened for Rb pathway lesions such as p16
INK4a point mutation or CDK6 amplification, with the identification of such lesions suggesting a higher probability of later cancer. Given the international epidemic of this cancer, such an approach appears sorely needed.
